Atovaquone
Therapeutic Category:
Antiprotozoal
Inhibits cytochrome bc₁ in mitochondria; blocks pyrimidine synthesis
Primary Use:
Treatment of Babesia, Pneumocystis, Toxoplasma, and Cytauxzoon
Effective against Babesia, Pneumocystis, Toxoplasma, and Plasmodium
Target Species:
Dogs, Cats, Cattle
Status:
Commercial
Monograph:
USP
Regulatory Status:
DMF
Disclaimer*
NGL FINE CHEM LIMITED is committed to protect the intellectual property (IP) generated in house and equally committed to respect the IP rights of all entities. Certain pipeline products may have valid patent(s) by other in India and/or in other jurisdictions. NGL offers such patented products for research and testing purpose only. The buyer will have the exclusive responsibility to respect the third party patent rights whether related to product or process.